Ilan Levinson, MD
Psychiatry · Stroudsburg, PANPI 1982625000
Payments from drug & device makers
Across 867 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AbbVie$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$909
- plus $5K from 26 others
What the payments were for
- Consulting fees$2001%
- Food & beverage$13,98997%
- Education$1611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 156 | $2,764 |
| AbbVie(2 entities) | 130 | $1,657 |
| Alkermes, Inc. | 76 | $1,559 |
| Teva Pharmaceuticals USA, Inc. | 80 | $1,439 |
| Otsuka America Pharmaceutical, Inc. | 67 | $1,120 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $909 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $872 |
| Supernus Pharmaceuticals, Inc. | 33 | $495 |
| Neurocrine Biosciences, Inc. | 26 | $475 |
| Axsome Therapeutics, Inc. | 19 | $433 |
| E.r. Squibb & Sons, L.L.C. | 29 | $430 |
| Lundbeck LLC | 25 | $390 |
| Vanda Pharmaceuticals Inc. | 17 | $297 |
| Sunovion Pharmaceuticals Inc. | 15 | $216 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Corium, LLC | 16 | $193 |
| Eisai Inc. | 10 | $148 |
| Ironshore Pharmaceuticals Inc. | 9 | $119 |
| Indivior Inc. | 7 | $115 |
| Noven Therapeutics, LLC | 5 | $96 |
| Merck | 6 | $89 |
| Shire North American Group Inc | 5 | $63 |
| Bausch Health US, LLC | 2 | $61 |
| Jazz Pharmaceuticals Inc. | 3 | $44 |
| Neos Therapeutics, LP | 2 | $41 |
| Noven Pharmaceuticals, Inc. | 1 | $23 |
| Neuronetics, Inc. | 2 | $22 |
| Biogen | 1 | $21 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Braeburn Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$200
How this compares
$14,350 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 158 | $611,781 |
| Invega TrinzaPaliperidone Palmitate | 41 | $385,872 |
| IngrezzaValbenazine Tosylate | 35 | $290,240 |
| AustedoDeutetrabenazine | 21 | $184,049 |
| Invega SustennaPaliperidone Palmitate | 46 | $156,892 |
| Abilify MaintenaAripiprazole | 47 | $136,122 |
| AuvelityDextromethorphan Hbr/Bupropion | 82 | $108,070 |
| RexultiBrexpiprazole | 62 | $97,634 |
| VraylarCariprazine Hcl | 46 | $67,454 |
| TrintellixVortioxetine Hydrobromide | 80 | $58,881 |
| CaplytaLumateperone Tosylate | 17 | $35,643 |
| Risperdal ConstaRisperidone Microspheres | 19 | $28,031 |
| Clozapine | 174 | $18,207 |
| Lurasidone Hcl | 47 | $14,787 |
| BelsomraSuvorexant | 33 | $13,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Trinza, Invega Sustenna, Risperdal Consta | $2,764 | $1,182,575264 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $475 | $290,24035 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,120 | $233,756109 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $1,439 | $186,70880 claims |
| Axsome Therapeutics, Inc.Auvelity | $433 | $108,07082 claims |
| AbbVieVraylar | $1,657 | $67,45446 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $872 | $58,88180 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $909 | $35,64317 claims |
| MerckBelsomra | $89 | $13,91833 claims |
| Shire North American Group IncMydayis | $63 | $4,28612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Stroudsburg
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.